Virtus LifeSci Biotech Clinical Trials ETF Rating $29.64 +0.66 (+2.28%) As of 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsRatingsShort InterestBuy This Stock Virtus LifeSci Biotech Clinical Trials ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BBC Aggregate RatingModerate Buy 2.66Holdings in BBC have an aggregate rating of Moderate Buy based on 233 analyst ratings issued in the past year covering 24 companies (32.9% of the portfolio).BBC Aggregate Price Target$29.64High Prediction$29.64Average Prediction$29.64Low Prediction$29.64Holdings in BBC have an aggregate price target of $29.64 and a range of $29.64 to $29.64 covering 24 companies (32.9% of the portfolio).BBC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy3 Buy rating(s)Moderate Buy17 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Virtus LifeSci Biotech Clinical Trials ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 24 BBC Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings2.30%CELCCelcuity$49.47-0.1%2.2442 of 5 stars2.67$56.50 14.2%6Analyst Forecast2.20%QUREuniQure$63.65+6.1%3.1114 of 5 stars2.83$71.75 12.7%12Trending NewsAnalyst ForecastAnalyst Revision1.74%OLMAOlema Pharmaceuticals$10.68-0.5%2.5854 of 5 stars2.63$23.33 118.5%8News CoverageAnalyst Forecast1.71%MLYSMineralys Therapeutics$39.39+5.1%2.3227 of 5 stars2.57$43.50 10.4%7Analyst Forecast1.64%RAPPRapport Therapeutics$26.74-1.2%2.97 of 5 stars2.80$35.33 32.1%5Analyst Forecast1.54%TRMLTourmaline Bio$47.85-0.1%1.4893 of 5 stars2.00$45.65 -4.6%11Analyst Forecast1.44%NTLAIntellia Therapeutics$25.46+4.0%3.8893 of 5 stars2.52$27.95 9.8%21Trending NewsAnalyst UpgradeGap Up1.38%ARWRArrowhead Pharmaceuticals$36.06-2.4%4.0851 of 5 stars2.78$43.14 19.6%9Analyst Forecast1.31%NUVBNuvation Bio$3.75+0.8%2.6555 of 5 stars2.88$7.86 109.5%8Analyst Forecast1.29%DNTHDianthus Therapeutics$34.752.9268 of 5 stars2.80$61.57 77.2%10Analyst Forecast1.28%STOKStoke Therapeutics$29.90-2.0%3.2034 of 5 stars3.00$25.57 -14.5%10Trending NewsAnalyst ForecastInsider TradeAnalyst Revision1.27%TERNTerns Pharmaceuticals$8.50+2.9%3.7992 of 5 stars2.43$15.49 82.2%7Analyst ForecastHigh Trading Volume1.25%COGTCogent Biosciences$16.19+3.9%2.478 of 5 stars2.77$20.00 23.5%13Analyst Forecast1.25%PRTAProthena$10.30-0.5%3.3129 of 5 stars2.20$20.50 99.0%10News CoverageAnalyst ForecastAnalyst Revision1.22%MAZEMaze Therapeutics$28.76+0.6%3.4301 of 5 stars3.00$33.83 17.6%9Analyst Forecast1.21%ABCLAbCellera Biologics$5.91-4.2%2.5995 of 5 stars2.71$8.00 35.4%7Positive NewsAnalyst Forecast1.20%CNTACentessa Pharmaceuticals$22.83+2.4%3.0006 of 5 stars2.91$32.38 41.8%11Analyst Forecast1.16%XERSXeris Biopharma$8.19-0.1%2.8084 of 5 stars2.57$7.08 -13.5%7News CoveragePositive NewsAnalyst Forecast1.09%CRVSCorvus Pharmaceuticals$7.25+3.6%1.853 of 5 stars2.50$13.00 79.3%4News CoverageAnalyst Forecast1.09%MRUSMerus$94.58+0.2%1.0821 of 5 stars2.16$93.12 -1.5%19Analyst Forecast1.08%MNMDMind Medicine (MindMed)$12.50-2.4%2.2853 of 5 stars3.00$26.50 112.0%9Analyst Forecast1.08%CYTKCytokinetics$60.31-0.8%3.6974 of 5 stars2.76$76.64 27.1%17Trending NewsAnalyst ForecastInsider Trade1.07%SIONSionna Therapeutics$28.35-0.5%2.7584 of 5 stars2.71$38.00 34.0%7Analyst ForecastInsider Trade1.06%LENZLENZ Therapeutics$46.25-4.8%0.7635 of 5 stars2.67$49.60 7.2%6Positive NewsAnalyst Forecast This page (NYSEARCA:BBC) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Clinical Trials ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Virtus LifeSci Biotech Clinical Trials ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
